Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC decreased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Rating) by 31.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 730 shares of the biopharmaceutical company’s stock after selling 335 shares during the period. Lazard Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $105,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. increased its holdings in Alnylam Pharmaceuticals by 0.9% in the second quarter. Oppenheimer & Co. Inc. now owns 5,056 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 44 shares in the last quarter. Kestra Advisory Services LLC increased its stake in Alnylam Pharmaceuticals by 5.8% in the 1st quarter. Kestra Advisory Services LLC now owns 1,339 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 74 shares in the last quarter. Signaturefd LLC increased its stake in Alnylam Pharmaceuticals by 8.1% in the 1st quarter. Signaturefd LLC now owns 998 shares of the biopharmaceutical company’s stock valued at $163,000 after purchasing an additional 75 shares in the last quarter. Commerce Bank raised its holdings in Alnylam Pharmaceuticals by 2.3% during the first quarter. Commerce Bank now owns 4,358 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 100 shares during the last quarter. Finally, D.A. Davidson & CO. boosted its position in Alnylam Pharmaceuticals by 2.5% during the second quarter. D.A. Davidson & CO. now owns 4,081 shares of the biopharmaceutical company’s stock worth $595,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 93.21% of the company’s stock.

Analyst Ratings Changes

ALNY has been the subject of a number of research analyst reports. BMO Capital Markets raised their price target on Alnylam Pharmaceuticals from $192.00 to $200.00 and gave the company a “market perform” rating in a research report on Friday, September 9th. JPMorgan Chase & Co. dropped their target price on shares of Alnylam Pharmaceuticals from $204.00 to $200.00 and set a “neutral” rating for the company in a report on Monday, October 24th. SVB Leerink upped their price target on shares of Alnylam Pharmaceuticals from $142.00 to $145.00 and gave the company a “market perform” rating in a report on Monday, November 7th. HC Wainwright lowered their price target on shares of Alnylam Pharmaceuticals from $430.00 to $415.00 and set a “buy” rating on the stock in a research report on Wednesday, November 2nd. Finally, Royal Bank of Canada lifted their price objective on Alnylam Pharmaceuticals from $225.00 to $250.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 20th. Seven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $232.37.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $209.41 on Wednesday. The company has a market cap of $25.76 billion, a P/E ratio of -21.43 and a beta of 0.54. The business has a fifty day simple moving average of $203.31 and a 200-day simple moving average of $177.49. Alnylam Pharmaceuticals, Inc. has a 52 week low of $117.58 and a 52 week high of $236.80. The company has a quick ratio of 3.33, a current ratio of 3.48 and a debt-to-equity ratio of 3.85.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) last posted its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported ($3.32) EPS for the quarter, missing the consensus estimate of ($1.77) by ($1.55). Alnylam Pharmaceuticals had a negative net margin of 123.02% and a negative return on equity of 430.74%. The business had revenue of $264.31 million during the quarter, compared to analysts’ expectations of $291.81 million. During the same quarter last year, the firm earned ($1.72) EPS. The firm’s quarterly revenue was up 40.9% compared to the same quarter last year. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -9.41 EPS for the current year.

About Alnylam Pharmaceuticals

(Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Featured Articles

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Rating).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.